Successful treatment with alectinib after crizotinib-induced hepatitis in ALK-rearranged advanced lung cancer patient: a case report

BACKGROUND: Besides the clinical benefit of crizotinib in ALK-rearranged metastatic non-small cell lung cancer (NSCLC), concerns about its hepatotoxicity have arisen. It is not clear whether this is a drug class side effect or if the use of other selective ALKs inhibitors is safe after this serious...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:BMC Pulm Med
Autors principals: Duarte, Flávia Amaral, Rodrigues, Leonardo Brand, Paes, Flávia Rocha, Diniz, Paulo Henrique Costa, Lima, Helena Flávia Cuba de Almada
Format: Artigo
Idioma:Inglês
Publicat: BioMed Central 2021
Matèries:
Case Report
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC7841898/
https://ncbi.nlm.nih.gov/pubmed/33509141
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12890-020-01390-6
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars